Biogrow SmoFlo Trial Program

Click here to download Biogrow^® SmoFlo^® Capsule Detailing Aid

Download Biogrow^® SmoFlo^® Capsule Detailing Aid

Click here to download Biogrow^® SmoFlo^® Capsule Leaflet

Download Biogrow^® SmoFlo^® Capsule Leaflet

No.

Title of Clinical/Review Paper

Conclusion

1

Thrombosis and COVID-19: The Potential Role of Nutrition

Fruitflow^® may serve as a safe antiplatelet prophylactic treatment for those at high risk of thrombotic complications and an alternative to pharmacological compounds associated with higher risk of bleeding.

2

Scientific Opinion on the modification of the authorisation of a health claim related to water-soluble tomato concentrate and helps to maintain a healthy blood flow and benefits circulation

EFSA journal on the approved health claim for Fruitflow^® – Helps maintain normal platelet aggregation, which contributes to healthy blood flow.

3

A randomised controlled trial comparing a dietary antiplatelet, the water-soluble tomato extract Fruitflow^®, with 75mg aspirin in healthy subjects

The suppression of platelet function of Fruitflow^® is milder and REVERSIBLE compared to aspirin. Hence, Biogrow SmoFlo Capsule which contains 150mg Fruitflow® is a healthier and natural alternative to aspirin as PRIMARY PREVENTION of cardiovascular diseases (CVDs).

4

Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans^1-3

Adenosine diphosphate (ADP)-induced platelet aggregation was significantly reduced 3 hours after supplementation with natural water-soluble tomato extract compared to baseline, and to control.

5

Consumption of Fruitflow^® lowers blood pressure in pre-hypertensive males: a randomised, placebo controlled, double blind, cross-over study

The consumption of a single dose of 150mg Fruitflow^® resulted in significant reduction of blood pressure and platelet aggregation in response to ADP, measured after 24 hours, compared to baseline, and to placebo.

6

Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans^1-3

ADP- and collagen-induced platelet aggregation were significantly reduced 3 hours after supplementation with doses of tomato extract equivalent to 6 and 2 tomatoes.

7

Fruitflow^®: the first European Food Safety Authority-approved natural cardio-protective functional ingredient

Fruitflow^® contains bioavailable antiplatelet compounds such as polyphenols, flavonoids and nucleosides which significantly inhibited platelet aggregation that can be of benefit to the people who are vulnerable to develop CVD.

8

Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk- a randomised, controlled trial

Standardised tomato extract contains cardioprotective components which play a significant role in the prevention of thrombosis and inflammation associated with plaque activation in hypertensive and obese patients.

9

Inhibitory effect of Fruitflow^® on platelet function: a randomized placebo-controlled trial in elderly subjects

Fruitflow^® suppressed platelet aggregation and decreased thromboxane B₂ (TXB₂), 6-keto-prostaglandin F_1α and platelet factor 4 (PF4) which indicates Fruitflow® might reduce the risk of thrombosis in CVDs.

10

The influence of adding tomato extract and acetylsalicylic acid to hypotensive therapy on the daily blood pressure profiles of patients with arterial hypertension and high cardiovascular risk

The use of standardised tomato extract is significant in arterial hypertension patients with high total CVD risk; it is associated with better blood pressure (BP) control and improvements in the daily BP profile.

11

Favourable hypotensive effect after standardised tomato extract treatment in hypertensive subjects at high cardiovascular risk: a randomised controlled trial

The addition of standardised tomato extract to standard antihypertensive therapy improves blood pressure control in hypertensive patients with high CVD risk.